Literature DB >> 34207596

Targeting HIF-1α Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL.

Candida Vitale1,2, Valentina Griggio1,2, Chiara Riganti3, Maria Todaro1,2, Joanna Kopecka3, Rebecca Jones1,2, Chiara Salvetti1,2, Elia Boccellato1,2, Francesca Perutelli1,2, Claudia Voena2, Laura Godio4, Mario Boccadoro1,2, Marta Coscia1,2.   

Abstract

The hypoxia-inducible factor 1 (HIF-1) and the CXCL12/CXCR4 axis regulate the interaction of chronic lymphocytic leukemia cells and the tumor microenvironment. However, the interconnections occurring between HIF-1 and the CXCL12/CXCR4 axis are not fully elucidated. Here, we demonstrate that the CXCL12/CXCR4 axis plays a pivotal role in the positive regulation of the α subunit of HIF-1 (HIF-1α) that occurs in CLL cells co-cultured with stromal cells (SC). Inhibitors acting at different levels on CXCR4 downstream signalling counteract the SC-induced HIF-1α upregulation in CLL cells, also hindering the SC-mediated pro-survival effect. HIF-1α inhibition also exerts off-tumor effects on the SC component, inducing the downregulation of target genes, including CXCL12. Consistently, our data show that pretreatment of leukemic cells and/or SC with idelalisib effectively abrogates the SC-mediated survival support. A combined on-tumor and off-tumor inhibition of HIF-1α was also observed in idelalisib-treated patients, who showed, along with a downregulation of HIF-1α target genes in leukemic cells, a significant decrease in CXCL12 serum concentration and changes in the bone marrow microenvironment. Our data demonstrate that the targeting of HIF-1α or its regulatory pathways acts at the tumor- and SC-level, and may be an appealing strategy to overcome the microenvironment-mediated protection of CLL cells.

Entities:  

Keywords:  CXCL12/CXCR4 axis; chronic lymphocytic leukemia; drug resistance; hypoxia inducible factor-1α; tumor microenvironment

Year:  2021        PMID: 34207596     DOI: 10.3390/cancers13122883

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  3 in total

1.  HIF-PH Encoded by EGLN1 Is a Potential Therapeutic Target for Chronic Lymphocytic Leukemia.

Authors:  Wancheng Guo; Daomiao Liang; Peilong Wang; Le Yin; Huifang Zhang; Cheng Xing; Zineng Huang; Yinghua Wu; Heng Li; Zhao Cheng; Xiaojuan Xiao; Jing Liu; Zhihua Wang; Hongling Peng
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-10

Review 2.  Hypoxic stress and hypoxia-inducible factors in leukemias.

Authors:  Daniela Magliulo; Rosa Bernardi
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

Review 3.  Protein Phosphorylation and Redox Status: An as Yet Elusive Dyad in Chronic Lymphocytic Leukemia.

Authors:  Mario Angelo Pagano; Federica Frezzato; Andrea Visentin; Livio Trentin; Anna Maria Brunati
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.